Your browser is no longer supported. Please, upgrade your browser.
Settings
SUPN Supernus Pharmaceuticals, Inc. daily Stock Chart
SUPN [NASD]
Supernus Pharmaceuticals, Inc.
Index- P/E11.15 EPS (ttm)1.97 Insider Own1.10% Shs Outstand51.87M Perf Week0.00%
Market Cap1.14B Forward P/E14.95 EPS next Y1.47 Insider Trans1.28% Shs Float50.67M Perf Month-17.58%
Income105.80M PEG0.30 EPS next Q0.61 Inst Own98.94% Short Float12.67% Perf Quarter-19.25%
Sales408.20M P/S2.78 EPS this Y63.20% Inst Trans0.10% Short Ratio9.72 Perf Half Y-33.37%
Book/sh10.62 P/B2.06 EPS next Y-29.90% ROA10.10% Target Price25.67 Perf Year-48.24%
Cash/sh5.72 P/C3.83 EPS next 5Y37.00% ROE21.00% 52W Range19.35 - 49.25 Perf YTD-34.08%
Dividend- P/FCF8.64 EPS past 5Y22.00% ROI14.70% 52W High-55.25% Beta1.57
Dividend %- Quick Ratio2.70 Sales past 5Y102.50% Gross Margin95.90% 52W Low13.90% ATR1.13
Employees448 Current Ratio2.90 Sales Q/Q-0.90% Oper. Margin36.10% RSI (14)36.65 Volatility2.51% 3.92%
OptionableYes Debt/Eq0.61 EPS Q/Q4.60% Profit Margin25.90% Rel Volume1.04 Prev Close21.90
ShortableYes LT Debt/Eq0.61 EarningsNov 05 AMC Payout0.00% Avg Volume659.97K Price22.04
Recom2.50 SMA20-10.08% SMA50-15.45% SMA200-30.55% Volume114,846 Change0.64%
Nov-08-19Downgrade Berenberg Buy → Hold
Nov-07-19Downgrade Stifel Buy → Hold $55 → $23
Nov-06-19Downgrade Jefferies Buy → Hold $46 → $23
Nov-12-18Reiterated B. Riley FBR Buy $68 → $65
Jan-18-18Reiterated B. Riley FBR, Inc. Buy $54
Dec-28-17Reiterated B. Riley FBR, Inc. Buy $50 → $54
Dec-04-17Upgrade Janney Neutral → Buy
Nov-08-17Upgrade Stifel Hold → Buy $47
Oct-19-17Initiated FBR & Co. Buy $53
Sep-19-17Downgrade Stifel Buy → Hold $47
Jul-17-17Downgrade Piper Jaffray Overweight → Neutral
Jul-14-17Initiated Janney Neutral
Jun-01-17Upgrade Piper Jaffray Neutral → Overweight
Jul-18-16Downgrade Piper Jaffray Overweight → Neutral
Jul-18-16Downgrade Northland Capital Outperform → Market Perform
Feb-08-16Upgrade Jefferies Hold → Buy
Nov-05-15Reiterated Northland Capital Outperform $26 → $27
Oct-28-15Initiated Northland Capital Outperform $26
Jun-18-15Upgrade Jefferies Hold → Buy $11 → $18
Jun-18-15Reiterated Stifel Buy $15 → $22
Nov-19-19 02:18PM  Investors Who Bought Supernus Pharmaceuticals (NASDAQ:SUPN) Shares Five Years Ago Are Now Up 148% Simply Wall St.
Nov-12-19 06:14PM  Supernus Pharmaceuticals seeks FDA approval for ADHD drug American City Business Journals
04:05PM  Supernus to Present at Two November Healthcare Conferences GlobeNewswire
07:20AM  The Daily Biotech Pulse: Reata, Kadmon Clinical Readouts, Apyx Medical's Earnings Beat Benzinga
Nov-11-19 04:15PM  Supernus Submits New Drug Application for SPN-812 for the Treatment of ADHD GlobeNewswire
Nov-09-19 03:46AM  Edited Transcript of SUPN earnings conference call or presentation 6-Nov-19 2:00pm GMT Thomson Reuters StreetEvents
Nov-08-19 03:53AM  How to Profit From Market Overreactions TheStreet.com
Nov-07-19 07:18AM  The Daily Biotech Pulse: Obseva Sinks On Adverse Clinical Readout, BioNano Surges On Saphyr Adoption, 2 IPOs Benzinga +6.12%
Nov-06-19 08:21AM  The Daily Biotech Pulse: Sesen Rallies On Positive FDA Meeting, Supernus Flunks Late-Stage ADHD Trial, GW Pharma Earnings Benzinga -31.58%
Nov-05-19 06:45PM  Supernus Pharmaceuticals (SUPN) Q3 Earnings and Revenues Lag Estimates Zacks
04:55PM  Supernus Announces Third Quarter 2019 Financial Results and Topline Data from Phase III Study of SPN-810 for Treatment of Impulsive Aggression (IA) in ADHD Patients GlobeNewswire
Oct-29-19 10:32AM  Supernus Pharmaceuticals (SUPN) Reports Next Week: Wall Street Expects Earnings Growth Zacks
Oct-28-19 08:53AM  Were Hedge Funds Right About Dumping Supernus Pharmaceuticals Inc (SUPN)? Insider Monkey
Oct-24-19 04:10PM  Supernus to Host Third Quarter 2019 Earnings Conference Call GlobeNewswire
Oct-22-19 03:49PM  Estimating The Fair Value Of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Simply Wall St.
Oct-02-19 01:04PM  Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Insiders Increased Their Holdings Simply Wall St.
Sep-25-19 02:21PM  Supernus to Present at the 2019 Cantor Global Healthcare Conference GlobeNewswire
Sep-13-19 01:54PM  5 Health Care Stocks Gurus Are Buying GuruFocus.com
Sep-02-19 09:50AM  How Does Investing In Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Impact The Volatility Of Your Portfolio? Simply Wall St.
Aug-30-19 06:00AM  There's Value In These 2 Small Beaten Down Biotech Stocks TheStreet.com
Aug-27-19 07:15PM  Supernus Pharmaceuticals Inc (SUPN) President, CEO Jack A. Khattar Bought $190,008 of Shares GuruFocus.com
Aug-26-19 11:20AM  Supernus to Present at Two September Healthcare Conferences GlobeNewswire
Aug-15-19 05:07PM  Edited Transcript of SUPN earnings conference call or presentation 7-Aug-19 1:00pm GMT Thomson Reuters StreetEvents
Aug-14-19 10:13AM  Can Value Investors Pick Supernus Pharmaceuticals (SUPN)? Zacks
08:04AM  These 4 Measures Indicate That Supernus Pharmaceuticals (NASDAQ:SUPN) Is Using Debt Safely Simply Wall St.
Aug-07-19 11:23PM  Supernus Pharmaceuticals Inc (SUPN) Q2 2019 Earnings Call Transcript Motley Fool -14.98%
Aug-06-19 08:15PM  Supernus Pharmaceuticals (SUPN) Q2 Earnings Top Estimates Zacks
04:41PM  Supernus Announces Second Quarter 2019 Financial Results GlobeNewswire
Jul-24-19 07:11AM  Do Supernus Pharmaceuticals's (NASDAQ:SUPN) Earnings Warrant Your Attention? Simply Wall St.
Jul-23-19 04:34PM  Supernus to Host Second Quarter 2019 Earnings Conference Call GlobeNewswire
Jul-11-19 12:58PM  4 Medical Stocks to Consider After Federal Judge Blocks Trump Proposal Zacks
Jun-17-19 12:39PM  How Do Analysts See Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Performing Over The Next Year? Simply Wall St.
Jun-11-19 11:04AM  Heres What Hedge Funds Think About Supernus Pharmaceuticals Inc (SUPN) Insider Monkey
Jun-05-19 07:04AM  Edited Transcript of SUPN earnings conference call or presentation 8-May-19 1:00pm GMT Thomson Reuters StreetEvents
May-30-19 03:03PM  Read This Before You Buy Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Because Of Its P/E Ratio Simply Wall St.
May-29-19 04:15PM  Supernus to Present at the Jefferies 2019 Global Healthcare Conference GlobeNewswire
May-16-19 08:10AM  5 Sizzling Small-Cap Stocks to Buy Today InvestorPlace
May-08-19 03:00PM  3 Top Value Stocks to Buy in May Motley Fool
May-07-19 10:14PM  EA, Supernus Pharmaceuticals, and More: Stocks on the Move After Hours Insider Monkey
07:35PM  Supernus Pharmaceuticals (SUPN) Lags Q1 Earnings and Revenue Estimates Zacks
06:31PM  Supernus: 1Q Earnings Snapshot Associated Press
05:09PM  Supernus Announces First Quarter 2019 Financial Results GlobeNewswire
May-05-19 10:22AM  Are Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Interest Costs Too High? Simply Wall St.
May-01-19 11:55AM  Heres What Hedge Funds Think About Supernus Pharmaceuticals Inc (SUPN) Insider Monkey
Apr-30-19 10:32AM  Analysts Estimate Supernus Pharmaceuticals (SUPN) to Report a Decline in Earnings: What to Look Out for Zacks
Apr-29-19 09:17AM  2 Incredibly Cheap Value Stocks to Buy Now Motley Fool
Apr-24-19 04:15PM  Supernus to Host First Quarter 2019 Earnings Conference Call GlobeNewswire
Apr-18-19 08:08AM  A Note On Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) ROE and Debt To Equity Simply Wall St.
Apr-01-19 04:46PM  Supernus' ADHD Candidate Positive in 4th Phase III Study Zacks
04:15PM  Supernus Announces Webcast of Investor Day on April 16, 2019 GlobeNewswire
10:57AM  Shareholders Are Thrilled That The Supernus Pharmaceuticals (NASDAQ:SUPN) Share Price Increased 296% Simply Wall St.
Mar-28-19 08:29PM  Edited Transcript of SUPN earnings conference call or presentation 8-Aug-18 1:00pm GMT Thomson Reuters StreetEvents
08:29PM  Edited Transcript of SUPN earnings conference call or presentation 27-Feb-19 2:00pm GMT Thomson Reuters StreetEvents
03:10PM  Supernus reports mixed ADHD drug trial results. So why isn't it worried? American City Business Journals
08:00AM  Supernus Announces P304 Phase III Data Confirming Positive Results from Previous Three Phase III Studies on SPN-812 in ADHD GlobeNewswire
Mar-27-19 06:03PM  Supernus Hosts Conference Call to Present Topline Results of Final Phase III Study for SPN-812 in Adolescents with ADHD GlobeNewswire
Mar-14-19 10:41AM  What Investors Should Know About Supernus Pharmaceuticals, Inc.s (NASDAQ:SUPN) Financial Strength Simply Wall St.
Mar-07-19 07:20AM  Recent Analysis Shows Golar LNG, AG Mortgage Investment Trust, AmerisourceBergen, Caesarstone, Dycom Industries, and Supernus Pharmaceuticals Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Mar-06-19 04:10PM  Supernus to Present at the 2019 Cowen Health Care Conference GlobeNewswire
Mar-01-19 02:48PM  Supernus Pharmaceuticals Inc (SUPN) Files 10-K for the Fiscal Year Ended on December 31, 2018 GuruFocus.com
02:22PM  New Enterprise Associates is raising its biggest fund yet. Here's how much it's going for. American City Business Journals
05:00AM  Supernus Pharmaceuticals- Migraines, Epilepsy and ADHD MoneyShow
Feb-27-19 03:09PM  Supernus Pharmaceuticals Inc (SUPN) Q4 2018 Earnings Conference Call Transcript Motley Fool +13.86%
07:00AM  Supernus Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Feb-26-19 04:56PM  Supernus Announces Record Full Year 2018 Financial Results GlobeNewswire
Feb-22-19 09:30AM  Should You Be Worried About Insider Transactions At Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)? Simply Wall St.
Feb-12-19 04:15PM  Supernus to Host Fourth Quarter and Full Year 2018 Earnings Conference Call GlobeNewswire
Feb-02-19 09:21AM  An Intrinsic Calculation For Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shows Its 45.76% Undervalued Simply Wall St.
09:12AM  3 Top Small-Cap Stocks to Buy Right Now Motley Fool
Jan-10-19 09:30AM  MYL vs. SUPN: Which Stock Is the Better Value Option? Zacks
06:23AM  Does Market Volatility Impact Supernus Pharmaceuticals, Inc.s (NASDAQ:SUPN) Share Price? Simply Wall St.
Dec-28-18 11:01AM  Edited Transcript of SUPN earnings conference call or presentation 7-Nov-18 2:00pm GMT Thomson Reuters StreetEvents
Dec-21-18 04:15PM  Supernus to Present at the 2019 J.P. Morgan Healthcare Conference GlobeNewswire -5.63%
Dec-20-18 10:57AM  Supernus Pharma's ADHD drug meets main goal in study on adolescents Reuters
09:56AM  Hedge Funds Arent Crazy About Supernus Pharmaceuticals Inc (SUPN) Anymore Insider Monkey
07:12AM  Supernus Pharma's ADHD drug meets main goal in late-stage trial Reuters
07:00AM  Supernus Announces Positive Results from Phase III Study For SPN-812 in Adolescents with ADHD GlobeNewswire
Dec-16-18 09:13AM  Why We Think Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Could Be Worth Looking At Simply Wall St.
Dec-14-18 04:02PM  Supernus Announces FDA Approval of sNDA to Expand Oxtellar XR® Label to Include Monotherapy GlobeNewswire
Dec-11-18 06:00AM  3 Top Biotech Stocks to Buy in December Motley Fool
Dec-06-18 12:53PM  This Index Of Leading Stocks Falls Into A Bear Market As Boeing Stings Dow Jones Investor's Business Daily -11.89%
12:33PM  Supernus Pharma's ADHD treatment fails to impress; shares fall Reuters
11:13AM  Here's Why Supernus Pharmaceuticals Is Sinking Today Motley Fool
08:00AM  Consolidated Research: 2018 Summary Expectations for TD Ameritrade Holding, Supernus Pharmaceuticals, Akcea Therapeutics, Dell Technologies, iRobot, and Pegasystems Fundamental Analysis, Key Performance Indications GlobeNewswire
07:56AM  The Daily Biotech Pulse: AbbVie Halts Lung Cancer Trial, Oncomed Merges With Mereo, Momenta Offering Benzinga
07:11AM  Supernus Pharma's ADHD treatment succeeds in two late-stage studies Reuters
07:00AM  Supernus Announces Positive Results from Two Phase III Studies For SPN-812 in Children with ADHD GlobeNewswire
Dec-05-18 04:12PM  Supernus Schedules Conference Call to Present Topline Results of Two Phase III Studies for SPN-812 in Children with ADHD GlobeNewswire
Dec-04-18 07:00AM  Today's Research Reports on Trending Tickers: Incyte and Supernus Pharmaceuticals ACCESSWIRE -5.83%
Nov-30-18 04:29PM  Stock Market Stages Bullish Reversal To Cap Week With Big Gains Investor's Business Daily +5.97%
Nov-29-18 06:55AM  Today's Research Reports on Trending Tickers: Heron Therapeutics and Supernus Pharmaceuticals ACCESSWIRE
Nov-15-18 11:06AM  What Should Investors Know About Supernus Pharmaceuticals Incs (NASDAQ:SUPN) Future? Simply Wall St.
Nov-07-18 04:39PM  Supernus to Present at Three November Healthcare Conferences GlobeNewswire +8.50%
08:24AM  3 Top Biotech Stocks to Buy in November Motley Fool
Nov-06-18 07:35PM  Supernus Pharmaceuticals (SUPN) Tops Q3 Earnings and Revenue Estimates Zacks
06:32PM  Supernus: 3Q Earnings Snapshot Associated Press
04:15PM  Supernus Announces Third Quarter 2018 Financial Results and Record Quarterly Revenue GlobeNewswire
Oct-26-18 08:25AM  Recent Analysis Shows Supernus Pharmaceuticals, GDS HOLDINGS, Golden Ocean Group, Golar LNG, Endo International plc, and 51job Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Oct-24-18 04:30PM  Supernus to Host Third Quarter 2018 Earnings Conference Call GlobeNewswire
Oct-15-18 08:15AM  Supernus Pharmaceuticals (SUPN): Moving Average Crossover Alert Zacks
Supernus Pharmaceuticals, Inc., a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy and migraine. The company's product candidates comprise SPN-812, a viloxazine hydrochloride, which is in Phase III clinical trial that is used for the treatment of attention deficit hyperactivity disorder (ADHD); SPN-810, a molindone hydrochloride that is in Phase III clinical trial for the treatment of impulsive aggression in patients with ADHD; SPN-809, a viloxazine hydrochloride, which is in Phase II ready clinical trial for the treatment of depression; SPN-604 extended release oxcarbazepine for bipolar; and SPN-817 that is in phase I clinical trial for treating epilepsy. The company markets its products through wholesalers and distributors. Supernus Pharmaceuticals, Inc. was founded in 2005 and is based in Rockville, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Khattar Jack A.President, CEOAug 23Buy26.397,200189,982465,141Aug 27 05:27 PM
SIEBERT JOHN MDirectorJun 20Option Exercise9.1310,00091,30055,742Jun 24 08:06 PM
SIEBERT JOHN MDirectorApr 25Option Exercise9.1310,00091,30045,742Apr 29 03:43 PM
PATRICK GREGORY SSr VP, Chief Financial OfficerFeb 27Option Exercise9.1320,000182,60067,896Feb 28 04:29 PM
PATRICK GREGORY SSr VP, Chief Financial OfficerFeb 27Sale41.5320,000830,65047,896Feb 28 04:29 PM